FinancialContent is the trusted provider of stock market information to the media industry.
Latest News about Joseph Pantginis
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
December 13, 2018
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
November 19, 2018
Analysts See 100% Upside To Rigel After Tavalisse Approval
April 18, 2018
Analyst Makes The Case For Ligand As A 'Core' Holding
September 05, 2017
Cytokinetics Still A Buy After Phase 2 SMA Data
March 23, 2017
Aptose Upgraded To Buy At Roth, Price Target Doubled
June 13, 2016
Flex Pharma Could Still Double From Here, Roth Analyst Says
January 06, 2016
Roth Capital's New Buy Rating On TetraLogic: 'SMAC'ing Cancer Around'
December 31, 2015
No Longer A Buy: Roth Capital Downgrades Keryx Biopharma, Slashes Price Target To $6
August 10, 2015
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
July 28, 2015
Cytokinetics Surges Amid Roth Capital Raising Its Price Target
December 31, 2014